HomeNewsBusinessCNBC-TV18 CommentsCadila's JV Hospira gets US nod: How will it impact Sun?
Trending Topics
Sensex Live
Pine Labs Share Price
Tenneco Clean Air India IPO
Groww IPO
Gold Rate

Cadila's JV Hospira gets US nod: How will it impact Sun?

Cadila Healthcare's joint venture partner Hospira won approval from US FDA for generic version of Sanofi-Aventis' cancer drug Taxotere. CNBC-TV18's Ekta Batra reports on how will this impact Sun Pharma and Cadila Health.

March 11, 2011 / 10:39 IST
Story continues below Advertisement
Remove Ad

Your browser doesn't support HTML5 video.

Cadila Healthcare

TAGS: #Aventis #Cadila Healthcare #cancer #CNBC-TV18 Comments #Hospira #Sanofi #Sun pharma #Taxotere
first published: Mar 10, 2011 03:37 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin telegram youtube
News
Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New
Features
Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube
Tools
SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4
Specials
PowerYourTrade Master Your Money Game Changers
Network 18 Sites
News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator
Quick Links
About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.